Urinary stress incontinence and overactive bladder

Intima treatment aims specifically to tighten and firm the anterior vaginal wall, thus restoring support to the base of the overlying bladder and urethra thereby improving the symptoms of urinary incontinence. There is also evidence showing that restoring bladder support reduces frequency of recurrent urinary tract infections.

The laser produces safe pulses of laser energy delivered via a tube shaped individual and sterile vaginal probe. These pulses generate laser beams which create microscopic channels of 0.7mm (700 microns) into the vaginal mucosa at closely spaced intervals. The process causes a mini–defect in the collagen making it shrink while stimulating new collagen and elastin to grow thus bulking and rejuvenating this layer.

Rotation of the probe at 360° allows treatment of the entire vaginal canal. This leads to an overall tightening of the lax vaginal walls including the upper part of the vagina producing added support for the base of the bladder and urethra.

The initial shrinkage and secondary regeneration also causes stretching of the internal bulbs and crura (structures) of the internal portion of the clitoris resulting in enhanced sexual sensation within the vagina.

The outcome of this procedure is the complete remodelling of the vaginal mucosa and the underlying collagen structure as well as the re-establishment of robust “younger-feeling” vaginal tissue enriched in thick and long collagen fibres. A clinical study showed that, at the three-month follow-up after the third treatment, 100% of women reported satisfaction with the treatment and 94% would recommend it to others. Additionally, 82% of women showed a statistically significant improvement in the vaginal health index.

Urolon is an innovative bioresorbable product used to treat Urinary Stress Incontinence (USI) in women. It’s made from microparticles of polycaprolactone (PCL) suspended in a gel carrier – all elements of which are FDA approved. The treatment, which is injected, stimulates the production of collagen which can replace lost tissue and thus counteract USI.

PCL is a well-known medical grade bioresorbable polymer used in many medical devices, such as dermal fillers, drug delivery devices, scaffolds for bone regeneration and resorbable sutures.

Bioresorption means that the body naturally breaks down and disposes of the materials used and produced by a treatment substance (in this case PCL) over time. This does mean that the effects of the treatment last only for a limited time before requiring a renewal. However it has the safety advantage that, should there be any negative effects, or simply a desire to change to an alternative treatment, the Urolon treatment is not permanently retained in the body and will gradually fade away, reducing the chance of long-term complications or of unwanted interactions with alternate treatments.

Although it varies for every person, Urolon should last for around 2 years until the bioresorption process removes it from your system.

After a thorough investigation and a clinical study Urolon was approved for use in Europe, with a CE certification. No serious complications occurred during the study, and the technology of this product is already being used in aesthetic dermatology, where over 1 million patients have been treated without significant issues.

Other regulatory processes are ongoing including the US FDA (although as noted above the elements of Urolon’s carrier gel are all regarded as safe by the FDA).

Urolon is injected into the Urethra, which will first have local anesthetic applied to minimize discomfort, as well as being a very quick 15-20 minute procedure, with the patient able to leave the clinic immediately post procedure.